STUDY | ADMIN | CCADMIN | ACCR. GOAL |
R E G |
O P E N |
ARM | TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
---|---|---|---|---|---|---|---|---|---|---|---|---|
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | PREV | 389 | 0 | Y | 0 Pre-Registration | 708 | 18 | 6 | 4 | 0 | 0 | |
708 | 18 | 6 | 4 | 0 | 0 | |||||||
1 | Y | 1 Blinded drug | 135 | 5 | 2 | 1 | 0 | 0 | ||||
2 Blinded drug | 36 | 0 | 0 | 0 | 0 | 0 | ||||||
3 Blinded drug | 35 | 0 | 0 | 0 | 0 | 0 | ||||||
4 Blinded drug | 143 | 10 | 4 | 2 | 2 | 0 | ||||||
349 | 15 | 6 | 3 | 2 | 0 | |||||||
S1007-Breast,Adj,N1,Endocrine+/-Chemo | BREAST | CCD | 9400 | 3 | Y | 4 Specimen Submission for CBALR TM Substudy | 173 | 15 | 4 | 3 | 0 | 0 |
173 | 15 | 4 | 3 | 0 | 0 | |||||||
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | SURV | 817 | 1 | Y | 0 Screening | 313 | 24 | 8 | 7 | 2 | 1 | |
313 | 24 | 8 | 7 | 2 | 1 | |||||||
2 | Y | 1 Carvedilol | 67 | 11 | 3 | 3 | 1 | 0 | ||||
2 No prophylaxis | 71 | 11 | 4 | 3 | 0 | 0 | ||||||
3 Observation | 155 | 0 | 0 | 0 | 0 | 0 | ||||||
293 | 22 | 7 | 6 | 1 | 0 | |||||||
S1600-Bladder,Radical Cystectomy Outcomes Nutrition | SXQOL | 200 | 1 | Y | 1 Blinded Nutrition Drink | 85 | 18 | 11 | 9 | 4 | 1 | |
2 Blinded Nutrition Drink | 92 | 19 | 8 | 4 | 1 | 0 | ||||||
177 | 37 | 19 | 13 | 5 | 1 | |||||||
S1703-Met Breast, STM-monitoring v Usual Care | CCD | SXQOL | 1320 | 1 | Y | 0 Screening | 429 | 95 | 50 | 29 | 7 | 1 |
429 | 95 | 50 | 29 | 7 | 1 | |||||||
2 | Y | 1 Control (Usual Care) | 142 | 29 | 21 | 12 | 5 | 2 | ||||
2 Intervention (STMDDM) | 139 | 27 | 15 | 8 | 2 | 0 | ||||||
281 | 56 | 36 | 20 | 7 | 2 | |||||||
S1706-Breast, Inflammatory, RT +/- Olaparib | BREAST | SXQOL | 300 | 1 | Y | 1 Olaparib + RT | 64 | 16 | 10 | 5 | 0 | 0 |
2 RT | 67 | 11 | 9 | 2 | 0 | 0 | ||||||
131 | 27 | 19 | 7 | 0 | 0 | |||||||
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | GU | SXQOL | 1273 | 1 | Y | 0 Induction SST | 686 | 127 | 61 | 40 | 12 | 3 |
686 | 127 | 61 | 40 | 12 | 3 | |||||||
2 | Y | 1 Standard Systemic Therapy Only | 245 | 48 | 26 | 16 | 7 | 2 | ||||
2 SST + Surgery/RT | 242 | 43 | 25 | 14 | 4 | 0 | ||||||
487 | 91 | 51 | 30 | 11 | 2 | |||||||
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | GU | SXQOL | 475 | 1 | Y | 0 Initial Registration | 423 | 121 | 59 | 35 | 9 | 1 |
423 | 121 | 59 | 35 | 9 | 1 | |||||||
2 | Y | 1 Chemo + RT | 199 | 59 | 25 | 14 | 3 | 0 | ||||
2 Chemo + RT + Atezolizumab | 204 | 61 | 34 | 21 | 6 | 1 | ||||||
403 | 120 | 59 | 35 | 9 | 1 | |||||||
S1823-GCT, Obs. Cohort, miRNA371 | PREV | 956 | 1 | Y | 1 Observation Arm | 746 | 238 | 120 | 72 | 30 | 9 | |
746 | 238 | 120 | 72 | 30 | 9 | |||||||
S1827-SCLC, MRI Surveillance +/- PCI | LUNG | SXQOL | 668 | 1 | Y | 1 PCI + MRI brain surveillance | 74 | 26 | 17 | 6 | 4 | 0 |
2 MRI brain surveillance | 76 | 28 | 16 | 8 | 5 | 1 | ||||||
150 | 54 | 33 | 14 | 9 | 1 | |||||||
S1904-Breast, Decision making for chemoprevention | PREV | 415 | 1 | Y | 1 Standard Education Materials | 127 | 48 | 25 | 12 | 3 | 0 | |
2 Support Tools + Standard Education Materials | 159 | 70 | 31 | 15 | 4 | 0 | ||||||
286 | 118 | 56 | 27 | 7 | 0 | |||||||
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | CCD | 536 | 1 | Y | 1 Financial Navigation | 41 | 28 | 18 | 8 | 2 | 0 | |
2 Control | 42 | 27 | 19 | 9 | 3 | 1 | ||||||
83 | 55 | 37 | 17 | 5 | 1 | |||||||
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | LUNG | SXQOL | 480 | 1 | Y | 1 Atezolizumab and SBRT | 107 | 55 | 33 | 16 | 4 | 1 |
2 SBRT | 101 | 51 | 25 | 13 | 2 | 0 | ||||||
208 | 106 | 58 | 29 | 6 | 1 | |||||||
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | LYMPH | SXQOL | 422 | 1 | Y | 1 CC-486 + R-miniCHOP | 30 | 14 | 4 | 4 | 3 | 0 |
2 R-miniCHOP | 26 | 11 | 4 | 4 | 1 | 0 | ||||||
56 | 25 | 8 | 8 | 4 | 0 | |||||||
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | LEUK | SXQOL | 247 | 1 | Y | 1 Delayed V-O | 24 | 15 | 9 | 3 | 1 | 0 |
2 Early V-O | 44 | 28 | 15 | 8 | 3 | 1 | ||||||
68 | 43 | 24 | 11 | 4 | 1 | |||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | SXQOL | 540 | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 4 | 4 | 4 | 4 | 1 | 0 | |
2 Patient Education | 3 | 3 | 3 | 3 | 1 | 0 | ||||||
7 | 7 | 7 | 7 | 2 | 0 | |||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | SXQOL | 2062 | 1 | Y | 1 Observation Arm | 1063 | 798 | 511 | 290 | 93 | 15 | |
1063 | 798 | 511 | 290 | 93 | 15 | |||||||
S2108CD-Genomic Tumor Board vs Usual Practice | CCD | 1182 | 1 | Y | 1 Usual Practice | 196 | 196 | 194 | 142 | 44 | 4 | |
2 EGTB Intervention | 161 | 161 | 157 | 104 | 41 | 8 | ||||||
357 | 357 | 351 | 246 | 85 | 12 | |||||||
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | SXQOL | 777 | 1 | Y | 0 | 0 | 0 | 0 | 0 | 0 | ||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | BREAST | SXQOL | 1 | E | 25 | 16 | 9 | 5 | 1 | 0 | ||
25 | 16 | 9 | 5 | 1 | 0 | |||||||
A021806-Pancreas, Perioperative vs Adjuvant Chemo | GI | SXQOL | 0 | E | 25 | 8 | 4 | 2 | 0 | 0 | ||
25 | 8 | 4 | 2 | 0 | 0 | |||||||
1 | E | 20 | 5 | 2 | 2 | 0 | 0 | |||||
20 | 5 | 2 | 2 | 0 | 0 | |||||||
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | GU | SXQOL | 1 | E | 107 | 19 | 8 | 4 | 1 | 0 | ||
107 | 19 | 8 | 4 | 1 | 0 | |||||||
2 | E | 72 | 14 | 6 | 4 | 1 | 0 | |||||
72 | 14 | 6 | 4 | 1 | 0 | |||||||
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | LUNG | SXQOL | 1 | E | 58 | 25 | 10 | 8 | 1 | 0 | ||
58 | 25 | 10 | 8 | 1 | 0 | |||||||
ACCL16N1-Guideline Consistent Treatment AYA ALL | CCD | 1 | T | 54 | 0 | 0 | 0 | 0 | 0 | |||
54 | 0 | 0 | 0 | 0 | 0 | |||||||
EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | GI | SXQOL | 1 | E | 23 | 8 | 4 | 3 | 3 | 1 | ||
23 | 8 | 4 | 3 | 3 | 1 | |||||||
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | MMYEL | SXQOL | 0 | E | 24 | 12 | 6 | 3 | 0 | 0 | ||
24 | 12 | 6 | 3 | 0 | 0 | |||||||
1 | E | 18 | 11 | 6 | 3 | 0 | 0 | |||||
18 | 11 | 6 | 3 | 0 | 0 | |||||||
2 | E | 8 | 6 | 1 | 1 | 1 | 0 | |||||
8 | 6 | 1 | 1 | 1 | 0 | |||||||
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT | BREAST | SXQOL | 1 | E | 16 | 8 | 6 | 3 | 2 | 1 | ||
16 | 8 | 6 | 3 | 2 | 1 | |||||||
2 | E | 16 | 7 | 5 | 3 | 3 | 1 | |||||
16 | 7 | 5 | 3 | 3 | 1 | |||||||
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction | SXQOL | OTHER | 1 | E | 3 | 3 | 3 | 1 | 0 | 0 | ||
3 | 3 | 3 | 1 | 0 | 0 | |||||||
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | GU | SXQOL | 1 | E | 6 | 1 | 1 | 1 | 0 | 0 | ||
6 | 1 | 1 | 1 | 0 | 0 | |||||||
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | GU | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | ||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST | LUNG | SXQOL | 1 | E | 2 | 0 | 0 | 0 | 0 | 0 | ||
2 | 0 | 0 | 0 | 0 | 0 | |||||||
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo | GI | SXQOL | 1 | E | 23 | 6 | 4 | 3 | 1 | 0 | ||
23 | 6 | 4 | 3 | 1 | 0 | |||||||
2 | E | 1 | 0 | 0 | 0 | 0 | 0 | |||||
1 | 0 | 0 | 0 | 0 | 0 | |||||||
A031801-GU, mRCC, Cabozantinib +/- Radium-223 | GU | SXQOL | 1 | E | 9 | 3 | 3 | 3 | 0 | 0 | ||
9 | 3 | 3 | 3 | 0 | 0 | |||||||
A031902-Pros, Adv, Enzalutamide + Rucaparib | GU | SXQOL | 0 | E | 5 | 1 | 1 | 0 | 0 | 0 | ||
5 | 1 | 1 | 0 | 0 | 0 | |||||||
1 | E | 5 | 1 | 1 | 0 | 0 | 0 | |||||
5 | 1 | 1 | 0 | 0 | 0 | |||||||
A032001-Blad, Met, Cabo +/- Avelumab after Chemo | GU | SXQOL | 1 | E | 7 | 7 | 6 | 4 | 2 | 0 | ||
7 | 7 | 6 | 4 | 2 | 0 | |||||||
A082002-Lung, Adv, Systemic Tx +/- SBRT | LUNG | SXQOL | 1 | E | 3 | 3 | 2 | 1 | 0 | 0 | ||
3 | 3 | 2 | 1 | 0 | 0 | |||||||
A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo | MELAN | SXQOL | 0 | E | 1 | 1 | 0 | 0 | 0 | 0 | ||
1 | 1 | 0 | 0 | 0 | 0 | |||||||
1 | E | 1 | 1 | 0 | 0 | 0 | 0 | |||||
1 | 1 | 0 | 0 | 0 | 0 | |||||||
A171901-NSCLC, > 70 Years Old, Pembro +/- Chemo | LUNG | SXQOL | 1 | E | 1 | 1 | 0 | 0 | 0 | 0 | ||
1 | 1 | 0 | 0 | 0 | 0 | |||||||
A191901-Brst, Text/Motivational Intervention ET Adher | CCD | 1 | E | 39 | 3 | 0 | 0 | 0 | 0 | |||
39 | 3 | 0 | 0 | 0 | 0 | |||||||
A212102-Blind Ref Set for Multicancer Early Detection | PREV | 1 | E | 35 | 35 | 34 | 7 | 3 | 0 | |||
35 | 35 | 34 | 7 | 3 | 0 | |||||||
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN | SXQOL | 1 | E | 8 | 3 | 1 | 1 | 0 | 0 | |||
8 | 3 | 1 | 1 | 0 | 0 | |||||||
2 | E | 6 | 1 | 0 | 0 | 0 | 0 | |||||
6 | 1 | 0 | 0 | 0 | 0 | |||||||
A222004-Mult, Olanza vs Megestrol for Anorexia | SXQOL | 1 | E | 2 | 0 | 0 | 0 | 0 | 0 | |||
2 | 0 | 0 | 0 | 0 | 0 | |||||||
A231602C-Blood Cancer, Assess Financial Difficulty | CCD | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | |||
4 | 0 | 0 | 0 | 0 | 0 | |||||||
A231901C-Breast, Shared Decision Engagement System | CCD | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||
1 | 0 | 0 | 0 | 0 | 0 | |||||||
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||
1 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo | OTHER | SXQOL | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | ||
4 | 0 | 0 | 0 | 0 | 0 | |||||||
EA2182-Anal, Erly, DECREASE | GI | SXQOL | 0 | E | 7 | 6 | 3 | 2 | 1 | 0 | ||
7 | 6 | 3 | 2 | 1 | 0 | |||||||
1 | E | 8 | 7 | 4 | 3 | 1 | 0 | |||||
8 | 7 | 4 | 3 | 1 | 0 | |||||||
EA2185-Panc, Impact of Panc Cyst Surveillance | PREV | SXQOL | 1 | E | 12 | 5 | 3 | 0 | 0 | 0 | ||
12 | 5 | 3 | 0 | 0 | 0 | |||||||
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 1 | E | 10 | 3 | 2 | 0 | 0 | 0 | ||
10 | 3 | 2 | 0 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
EA8183-Pros, Dbl Blind Andro Dep + Daro vs Placebo | GU | SXQOL | 0 | E | 12 | 5 | 1 | 0 | 0 | 0 | ||
12 | 5 | 1 | 0 | 0 | 0 | |||||||
1 | E | 4 | 1 | 1 | 0 | 0 | 0 | |||||
4 | 1 | 1 | 0 | 0 | 0 | |||||||
EA8184-Pros, Dbl Blind GTC vs Placebo | PREV | SXQOL | 0 | E | 3 | 3 | 1 | 1 | 0 | 0 | ||
3 | 3 | 1 | 1 | 0 | 0 | |||||||
1 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
EA8212-Blad, NMIBC, BRIDGE | GU | SXQOL | 1 | E | 22 | 22 | 22 | 18 | 7 | 2 | ||
22 | 22 | 22 | 18 | 7 | 2 | |||||||
EAA173-MYEL, SMM, Rd +/- Daratumumab | MMYEL | SXQOL | 0 | E | 49 | 12 | 7 | 5 | 2 | 2 | ||
49 | 12 | 7 | 5 | 2 | 2 | |||||||
1 | E | 22 | 3 | 1 | 1 | 0 | 0 | |||||
22 | 3 | 1 | 1 | 0 | 0 | |||||||
EAQ202-Improving AYA PROs in EA Trials | SXQOL | 1 | E | 43 | 16 | 1 | 0 | 0 | 0 | |||
43 | 16 | 1 | 0 | 0 | 0 | |||||||
NHLBIMDS-LEUK, National MDS Study | CCD | 1 | E | 207 | 44 | 23 | 11 | 0 | 0 | |||
207 | 44 | 23 | 11 | 0 | 0 | |||||||
NRGBN003-Mening, Grd II, Observation vs Irradiation | OTHER | SXQOL | 1 | E | 5 | 0 | 0 | 0 | 0 | 0 | ||
5 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 3 | 0 | 0 | 0 | 0 | 0 | |||||
3 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGBN007-Brain, New Dx, Ipi + Nivo vs Temozomide | OTHER | SXQOL | 1 | E | 8 | 0 | 0 | 0 | 0 | 0 | ||
8 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 5 | 0 | 0 | 0 | 0 | 0 | |||||
5 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGBN011-Brain, Lomustine + Temo vs Temo | OTHER | SXQOL | 1 | E | 5 | 5 | 2 | 1 | 0 | 0 | ||
5 | 5 | 2 | 1 | 0 | 0 | |||||||
2 | E | 2 | 2 | 1 | 0 | 0 | 0 | |||||
2 | 2 | 1 | 0 | 0 | 0 | |||||||
NRGBR007-Breast, Stg I, De-Escalation of Breast RT | BREAST | SXQOL | 1 | E | 3 | 3 | 1 | 0 | 0 | 0 | ||
3 | 3 | 1 | 0 | 0 | 0 | |||||||
2 | E | 3 | 3 | 1 | 0 | 0 | 0 | |||||
3 | 3 | 1 | 0 | 0 | 0 | |||||||
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO | PREV | SXQOL | 1 | E | 6 | 4 | 1 | 1 | 0 | 0 | ||
6 | 4 | 1 | 1 | 0 | 0 | |||||||
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy | GI | SXQOL | 1 | Y | 15 | 0 | 0 | 0 | 0 | 0 | ||
15 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGGU009-Pros, PREDICT-RT | GU | SXQOL | 1 | E | 18 | 17 | 7 | 5 | 1 | 0 | ||
18 | 17 | 7 | 5 | 1 | 0 | |||||||
2 | E | 16 | 15 | 7 | 3 | 1 | 0 | |||||
16 | 15 | 7 | 3 | 1 | 0 | |||||||
NRGGU010-Pros, Parallel De-Intens & Intens Trials | GU | SXQOL | 1 | E | 14 | 11 | 4 | 1 | 1 | 0 | ||
14 | 11 | 4 | 1 | 1 | 0 | |||||||
2 | E | 13 | 10 | 5 | 2 | 1 | 0 | |||||
13 | 10 | 5 | 2 | 1 | 0 | |||||||
NRGHN001-Nasopharyngeal , Indiviual Tx EBV | OTHER | SXQOL | 1 | E | 9 | 0 | 0 | 0 | 0 | 0 | ||
9 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 8 | 0 | 0 | 0 | 0 | 0 | |||||
8 | 0 | 0 | 0 | 0 | 0 | |||||||
3 | E | 7 | 0 | 0 | 0 | 0 | 0 | |||||
7 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGHN005-HN, early stg P16-pos, randomize de-intensifi | OTHER | SXQOL | 1 | E | 7 | 1 | 0 | 0 | 0 | 0 | ||
7 | 1 | 0 | 0 | 0 | 0 | |||||||
NRGHN006-HN, Erly Stg, Biopsy vs Dissection | OTHER | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | ||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
2 | E | 2 | 1 | 1 | 1 | 0 | 0 | |||||
2 | 1 | 1 | 1 | 0 | 0 | |||||||
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | OTHER | SXQOL | 1 | E | 6 | 4 | 3 | 3 | 1 | 0 | ||
6 | 4 | 3 | 3 | 1 | 0 | |||||||
NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | LUNG | SXQOL | 1 | E | 13 | 0 | 0 | 0 | 0 | 0 | ||
13 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGLU006-Meso, Stg I-IIIA, Pleurectomy +/- Adj RT | LUNG | SXQOL | 1 | E | 2 | 2 | 0 | 0 | 0 | 0 | ||
2 | 2 | 0 | 0 | 0 | 0 | |||||||
2 | E | 2 | 2 | 1 | 1 | 0 | 0 | |||||
2 | 2 | 1 | 1 | 0 | 0 | |||||||
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux | OTHER | SXQOL | 1 | E | 6 | 1 | 1 | 1 | 0 | 0 | ||
6 | 1 | 1 | 1 | 0 | 0 | |||||||
2 | E | 5 | 1 | 1 | 1 | 0 | 0 | |||||
5 | 1 | 1 | 1 | 0 | 0 | |||||||
R1308-Lung, Stg II/III, Photon vs Proton Chemo RT | LUNG | SXQOL | 1 | E | 1 | 0 | 0 | 0 | 0 | 0 | ||
1 | 0 | 0 | 0 | 0 | 0 | |||||||
Study | Admin | CCAdmin | Registration/Phase | Open Date |
---|---|---|---|---|
S2205 ICE COMPRESS: Reduction of CIPN from Taxanes | SXQOL | 1 Registration | 16-Mar-23 | |
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 2 Late Randomization Callback | 08-May-17 |
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 2 Randomization2 | 08-Sep-17 |
EA8184 Pros, Dbl Blind GTC vs Placebo | PREV | SXQOL | 1 Randomization | 20-May-21 |